Reply post for discussion for benefits and risks of contraception

Inital Post:

Reply to this:
This is quite a controversial issue but as a woman I believe that we must be aware and educate both our children in terms of contraceptive care and always keep updated information on each one that is going to be consumed. From my point of view I would use it and suggest it to my friends for their teenagers as long as they were educated and knew everything about it.
Oral contraception (OC) with steroid substances chemically and biologically related to natural hormones, involved in the control of the menstrual cycle and ovulation, constitutes one of the most important milestones in the history and evolution of gynecology. , humanity has starred in a true cultural revolution and its user has not only enjoyed its contraceptive effect, but also medical benefits that positively improve their health. As hormonal contraception is generally indicated for healthy women and can be administered for a long period of time, it has been related to the development of various diseases; the one that concerns us today is venous thromboembolic disease.
The incidence of venous thromboembolism (VTE) (1) in young women not using OCs of reproductive age is 2-4 per 10,000 / year; OC users, including low-dose users, is 9-11 per 10,000 women / year; in pregnant women, the risk is 29 per 10,000 women / year. For many years, the effects of OCs on the coagulation and fibrinolytic systems have been studied (2,3). The thrombotic phenomenon is a process related to hemostatic and vascular alterations, with a response of plasma hypercoagulability and hyperfibrinolysis. Many of the hemostatic changes have been related to the dose of ethinyl estradiol (EE). It is important that women are aware of the risk of VTE and its signs and symptoms, and that doctors take into account the individual risk factors of each woman when prescribing a contraceptive.
 Dinger JC, Heinemann LAJ, Khul-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observation. Contraception. 2007;75(5):344- 354. 
Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. BMJ 1969;2:651-7. 6 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC,

Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.